0

chemotherapy for breast cancer stage 2

Tài liệu Screening for Breast Cancer: Systematic Evidence Review Update for the U. S. Preventive Services Task Force doc

Tài liệu Screening for Breast Cancer: Systematic Evidence Review Update for the U. S. Preventive Services Task Force doc

Sức khỏe giới tính

... for BreMortalityast Cancer (95% CrI)NNI to Prevent 1 Breast Cancer Death (95% CrI) 20 02 Review (age 65-74y); Humphrey, et al, 20 02 2,3 Malmo and Swedish 2- Ctrialsounty 2 0.78 (0. 62- 0.99) ... Overdiagnosis 20 Key Question 2b. What are the harms associated with CBE? 22 Key Question 2c. What are the harms associated with BSE? 22 Chapter 4. Discussion 23 Summary 23 Limitations 24 Future ... fair quality (Table 2) . 2 For women age 40-49 years, results of the 20 02 meta-analysis indicated a relative risk for breast cancer mortality of 0.85 (95% CrI, 0.73-0.99) for women randomly...
  • 95
  • 1,014
  • 0
Tài liệu SCREENING FOR BREAST CANCER WITH MAMMOGRAPHY ppt

Tài liệu SCREENING FOR BREAST CANCER WITH MAMMOGRAPHY ppt

Sức khỏe giới tính

... treatment for breast cancer in Norway: comparative analysis of cancer registry data. BMJ 20 11;343:d46 92. 20 . NHS cancer screening programmes. BASO Breast Audit 1999 /20 00. www.cancerscreening.nhs.uk/breastscreen/publications.html ... background for our information in this leaflet below. SCREENING FOR BREAST CANCER WITH MAMMOGRAPHY What are the benefits and harms of attending a screening programme for breast cancer? ... accounts for most of the observed breast cancer specifi c mortality reductions in Australian women since the national screening program began in 1991. Breast Cancer Res Treat. Epub 20 11 Sep 29 ....
  • 15
  • 528
  • 3
Báo cáo sinh học:

Báo cáo sinh học: " Encapsulation of docetaxel in oily core polyester nanocapsule intended for breast cancer therapy" pptx

Điện - Điện tử

... NCs. The NCs' mean diameters were 127 .5 ± 19 .2 nm for NC-PLA206, 123 .8 ± 0.9 nm for NC-PLA207, 110.8 ± 8.6 nm for NC-PLA208, and 124 .6 ± 3.1 nm for NC-PCL. These findings indicated a statistically ... poly(lactic acid)/polystyrene blends. J Polym Sci B Polym Phys 20 02, 40 :22 48 -22 58. [47] Kirchner B: Ionic Liquids. Volume 29 0. Berlin: Springer; 20 10. [48]. Li PY, Lai PS, Hung WC, Syu WJ: Poly(l-lactide)-vitamin ... 3; S.D.: standard deviation between the three assays: PLA206 (105 kDa), PLA207 (20 9 kDa), PLA208 (25 0 kDa), and PCL ( 72 kDa). Figure 2. Influence of PVA concentrations (A,B) and molecular weights...
  • 24
  • 474
  • 0
Báo cáo hóa học:

Báo cáo hóa học: " A Novel Docetaxel-Loaded Poly (e-Caprolactone)/Pluronic F68 Nanoparticle Overcoming Multidrug Resistance for Breast Cancer Treatment" pot

Hóa học - Dầu khí

... 3)PolymerPCNP 29 3 .2 ± 3.6 0.1 72 9.76 65.08 -48.70 ± 3.11 PCLPFNP 20 1.7 ± 10.1 0.096 10. 02 69.10 - 12. 50 ± 0.86 PCL/F68CCNP 28 1 .2 ± 5.5 0.145 -35.70 ± 2. 99 PCLCFNP 22 2.7 ± 5.4 0.133 -20 .50 ± 1.34 PCL/F68Note: ... inhuman breast cancer cells and therefore have considerablepotential for treatment of breast cancer. Keywords Nanoparticles Á MDR Á Pluronic F68 ÁPoly (e-caprolactone) Á Docetaxel Á Breast cancer Introduction Cancer ... drugs. Biomaterials 26 , 27 13 27 22 (20 05) 27 . M.P. Desai, V. Labhasetwar, E. Walter, R.J. Levy, G.L. Amidon,The mechanism of uptake of biodegradable microparticles inCaco -2 cells is size dependent....
  • 10
  • 363
  • 0
Báo cáo sinh học:

Báo cáo sinh học: "Reasons for breast cancer heterogeneity" pptx

Báo cáo khoa học

... more precise molecular classification of breast tumors.BioMed CentralJournal of Biology 20 08, 77::6Published: 22 February 20 08Journal of Biology 20 08, 77::6 (doi:10.1186/jbiol67) The ... understood breast cancer heterogeneitybetter. Two recent papers in Genome Biology from thelaboratories of Carlos Caldas [1] and Eric Miska [2] usemolecular methods to classify breast cancers ... tumorigenicity in breast cancer cells [14] and also invasion and metastasis[15,16]. They are thought to be important in oncogenesis(see [17,18] for reviews).6 .2 Journal of Biology 20 08, Volume...
  • 4
  • 422
  • 0
báo cáo khoa học:

báo cáo khoa học: "Axillary lymph node dissection for breast cancer utilizing Harmonic Focus®" pps

Báo cáo khoa học

... seromas following breast cancer surgeries. Breast J 20 07, 13:588- 92. 21 . Burak WE Jr, Goodman PS, Young DC, Farrar WB: Seroma formationfollowing axillary dissection for breast cancer: risk factors ... Winer EP, Wolff AC, NCCN Breast Cancer Clinical PracticeGuidelines Panel: Breast cancer. Clinical practice guidelines in oncology. JNatl Compr Canc Netw 20 09, 7 (2) : 122 - 92. 4. Giuliano AE, Hunt ... CS, Nelson BK: Seroma formationfollowing breast cancer surgery. Breast J 20 03, 5:385-8.10. Woodworth PA, McBoyle MF, Helmer SD, Beamer RL: Seroma formationafter breast cancer surgery: incidence...
  • 5
  • 349
  • 0
báo cáo khoa học:

báo cáo khoa học: "Clinical relevance of "withdrawal therapy" as a form of hormonal manipulation for breast cancer" doc

Báo cáo khoa học

... localizedestrogen receptors in human breast cancer. Cancer Res 1990,50 12: 3545-3550.9. British Breast Group: Assessment of response to treatment in advanced breast cancer. Lancet 1974, 2: 38-39.10. Hayward ... estradiol hypersensitivity in human breast cancer cells. J ClinEndocrinol Metab 1995, 8010 :29 18 -29 25.15. SOLE trial Newsletter No 8, March 20 11. [http://www.breastinternationalgroup.org/LinkClick.aspx?fileticket=dmcZc0avwBc%3d&tabid =23 41].doi:10.1186/1477-7819-9-101Cite ... Surgical Oncology 20 11, 9:101http://www.wjso.com/content/9/1/101Page 2 of 4RESEARC H Open AccessClinical relevance of “withdrawal therapy” as aform of hormonal manipulation for breast cancer Amit...
  • 4
  • 253
  • 0
báo cáo khoa học:

báo cáo khoa học: "Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer" pdf

Báo cáo khoa học

... 0.000 Hemoglobin 121 . 72 21 . 92 123 .93 28 .26 0.417 Serum albumin 42. 83±4 .25 42. 18±4. 62 0 .21 1 CEA 15.986±67.377 4.357±9.1 92 0.081 CA199 175.836±803.631 81 .27 0±394.9 42 0 .25 5 Comorbid illness ... and 22 Table 2 Patient preoperative status NACT (%) n =110 SURG (%) n =26 7 P value Body mass index (BMI) 22 . 92 3. 12 23.03±3.56 0.773 White blood cells 5 .29 ±1.84 6 .25 2. 10 0.000 ... 21 -T2 -T3 -T4 90(81.8%)/ 73(66.4%) 20 (18 .2% )/ 12( 10.9%) 25 1(94%) /22 1( 82. 8%) 16(6.0%)/17(6.4%) Pathological N Staging -N0 -N1 -N2 -N3 34(30.9%) 47( 42. 7%) 17(15.5%) 12( 10.9%)...
  • 27
  • 239
  • 0
Báo cáo khoa học:

Báo cáo khoa học: "Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer" pot

Báo cáo khoa học

... Pharmacol1983, 32: 2045 -20 52. 20 . Wolf DM, Jordan VC: Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol 19 92, 45 (2) :118 -28 . 21 . Wiebe VJ, ... Agency for Researchon Cancer, Lyon, France 1996, 66 :25 3-365.11. Swerdlow AJ, Jones ME: Tamoxifen treatment for breast cancer and riskof endometrial cancer: a case-control study. J Natl Cancer ... tamoxifen for prevention of breast cancer. Br J Cancer 1989, 60(1): 126 -31.4. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM:Endometrial cancer in tamoxifen-treated breast cancer...
  • 3
  • 427
  • 0
Báo cáo khoa học:

Báo cáo khoa học: "Predictive factors for breast cancer in patients diagnosed atypical ductal hyperplasia at core needle biopsy" doc

Báo cáo khoa học

... Yes 8 (25 .8%) 4 (50%) 33.3% 0.186No 23 (74 .2% ) 4 (50%) 14.8%Mass + MIC on MMG Yes 1 (3.1%) 2 (22 .2% ) 66.7% 0. 52 No 31 (96.9%) 7 (77.8%) 18.4%Lesion size 1 cm 23 (69.7%) 3 (30%) 11.5% 0. 024 > ... 1.147 -25 .105 0.033Mass USG 2. 667 0 .29 2 -24 .345 0.385MIC USG 4.571 0.758 -27 .577 0.097Mass + MIC USG 14.571 1.315-161.418 0. 029 Needle size 1.50 0.155-14.557 0. 727 Number of cores 1.50 0 .24 4-9 .21 9 ... Underestimationrate (22 .2% )P value(Chi-square)Benign (n = 35) Malignancy (n = 10)Age (years) < 50 28 (80%) 3 (30%) 9.7% 0.00350 7 (20 %) 7 (70%) 50%Mass on MMG Yes 10 ( 32. 3%) 4 (50%) 28 .6% 0.351No 21 ...
  • 5
  • 319
  • 0

Xem thêm